DATROWAY ® (datopotamab deruxtecan) has been approved in the ... The DXd ADC portfolio currently consists of ENHERTU, a HER2 directed ADC, and DATROWAY, a TROP2 directed ADC, which are being ...

Enhertu (fam-trastuzumab deruxtecan-nxki) is currently indicated as a second-line therapy for HER2-positive metastatic breast cancer.

The trial aims to assess the safety and efficacy of Enhertu, either as a single agent or with pertuzumab, against the THP.

The DESTINY-Breast09 Phase III trial of AstraZeneca (LSE: AZN) and Daiichi Sankyo’s (TYO: 4568) Enhertu (trastuzumab ...

Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the ...

Interim results from a Phase III trial showed the combo benefited HER2-positive metastatic breast cancer patients in the first-line setting.

Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive ...

Scientists say a newly discovered green comet likely has broken apart and won’t be visible to the naked eye. Comet SWAN hails ...

In the Phase III DESTINY-Breast09 trial, Enhertu (trastuzumab deruxtecan) and Perjeta (pertuzumab) significantly improved ...

The data could help the Enhertu regimen overtake a drug combination that’s been used as the initial treatment for ...

Condor Partners and Northlight Capital Partners, with JP Partners brokering the deal, are pleased to announce new funding for Mural Park, a 200,000-square-foot, Class A office project in Chicago, ...

Packet capture authority Endace today announced an integration between EndaceProbe and Microsoft Sentinel, a next-generation cloud security, information, and event management (SIEM) solution. The ...